Mark Lynch
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, Single-cell and spatial transcriptomics, Clostridium difficile and Clostridium perfringens research, Colorectal and Anal Carcinomas
Most-Cited Works
- → Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck(2016)4,966 cited
- → BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis(2004)4,005 cited
- → Discovery and development of sorafenib: a multikinase inhibitor for treating cancer(2006)1,812 cited
- → Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5(2006)1,531 cited
- → Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling(2008)1,428 cited
- → Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity(2010)1,313 cited
- → Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression(2018)786 cited
- → Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models(2006)463 cited
- → Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial(2017)421 cited
- → Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM(2016)235 cited